Phaseline

Companies › Estrella Immunopharma

Estrella Immunopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EB103
Autologous T-cell therapy transduced with lentiviral vector expressing the EB103 transgene
–Phase 1B-Cell Non-Hodgkin's Lymphoma (NHL)Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06343311EB103Phase 1B-Cell Non-Hodgkin's Lymphoma (NHL)OncologyJul 2027

From the company's SEC filings

Cash of $0m on 2026-06-30; operating cash outflow about $17m a year; runway about 0 months at that burn, to Jul 2026

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.